EGFR and lung adenocarcinoma: The hypothesis is that skin sample studies from EGFR‐mutated lung adenocarcinoma patients allow us to establish a relationship between EGFR expression or its signaling pathway derivatives, and gefitinib treatment response, potentially acting as a tool to avoid tumor biopsy related risks.